Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push

Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio.